Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heated Drug Pricing Debate Fanned By Election, Teva's Olafsson Says

Executive Summary

'I can't wait until it's over,' Teva's Generic Medicines CEO Sigurdur Olafsson said of the US Presidential election; then the current debate around drug pricing will return to a discussion of value, he predicted.


Related Content

Pricing Transparency Policies Not Suited To Generics, GPhA Argues
Teva Seeds OTC Growth Synergies With Former Allergan Business
EpiPen Familiarity May Prove Tough Hurdle For Generics
Allergan's Price Reform Pledge: Will Others Follow?
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts